Mood Disorders  >>  lisdexamfetamine  >>  Phase 3
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lisdexamfetamine / Generic mfg.
NCT01436162 / 2011-003006-25: Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

Completed
3
1105
Europe, US, RoW
Antidepressant + SPD489 (Lisdexamfetamine dimesylate ), Vyvanse, Antidepressant + Placebo
Shire
Major Depressive Disorder
12/13
12/13
NCT01436149 / 2011-003018-17: Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

Completed
3
1262
Europe, Canada, US, RoW
SPD489 (Lisdexamfetamine dimesylate ), Vyvanse, Placebo
Shire
Major Depressive Disorder
12/13
12/13
NCT01093963: Efficacy Study of Lisdexamfetamine to Treat Bipolar Depression

Terminated
3
25
US
Lisdexamfetamine, Placebo
Lindner Center of HOPE, Shire, University of Cincinnati
Bipolar Depression
02/14
02/14
NCT01131559: Adjunctive Lisdexamfetamine (LDX) in Bipolar Depression

Terminated
3
50
US
Lisdexamfetamine, Vyvanse, Placebo control, Sugar pill, fake pill with no active medication
Lindner Center of HOPE, Shire, University of Cincinnati
Bipolar, Depression
02/14
02/14
NCT01436175 / 2011-003019-47: SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study

Terminated
3
1570
Europe, Canada, US, RoW
SPD489 (Lisdexamfetamine dimesylate) + Antidepressant, Vyvanse, LDX
Shire
Major Depressive Disorder
03/14
03/14

Download Options